For Chinese Companies

We have introduced excellent Japanese pharmaceutical products to Beijing Tide Pharmaceutical Co., Ltd. and have supported its development. For example, we have supported the introduction of Lipo-PGE1 developed by TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. and Mitsubishi Tanabe Pharma Corporation, Lipo-NSAID developed by KAKEN PHARMACEUTICAL CO.,LTD., as well as flurbiprofen patch developed by Mikasa Seiyaku Co., LTD., both of which have recorded sales of over 20 billion yen. We have also concluded a capital and business agreement with Sino Biopharmaceutical Co., Ltd. Group (the parent company of Beijing Tide Pharmaceutical Co., Ltd.), and are currently engaged in the business of introducing not only excellent Japanese pharmaceutical products, but also pharmaceutical products, active pharmaceutical ingredients, and pharmaceutical materials owned by Sino Biopharmaceutical Co., Ltd. Group to Japanese companies.

Thus, we have the know-how and personal connections gained through more than 30 years of pharmaceutical development in Japan, and more than 20 years of experience and achievements in successfully introducing and developing excellent Japanese pharmaceuticals to Chinese companies. We believe that these experiences will be useful for Chinese companies that want to introduce excellent Japanese pharmaceuticals and for Chinese companies that want to license or sell APIs in Japan. We have launched a business to support such Chinese companies, so please feel free to contact us. Please understand that we may decline your proposal if it conflicts with the business of the China Bio-Pharmaceuticals Group.